Key Highlights
- Robert Watson appointed as Chairperson of CEL-SCI Board.
- Watson brings over 40 years of healthcare market experience.
- Significant expertise in capital formation and partnerships.
- Multikine immunotherapy shows promising results in head and neck cancer treatment.
- FDA confirms small, focused Registration Study for Multikine.
Source: Business Wire
Notable Quotes
- “I have greatly appreciated Bob’s guidance as a Director of CEL-SCI. His recent retirement from an active CEO role created the bandwidth for him to assume additional responsibilities as our Chairperson. The team and I are excited to have Bob involved at this level where his capital markets expertise will be highly valuable.” — Geert Kersten, CEO at CEL-SCI
- “Having been on the path with CEL-SCI toward FDA approval of Multikine, it is my honor to be able to stand side by side with the management team as we complete the final leg of this amazing journey to bring a pre-surgical immunotherapy to patients with head and neck cancer.” — Robert Watson, Chairperson of the Board at CEL-SCI Corporation
SoHC's Take
CEL-SCI’s decision to appoint Robert Watson as Chairperson of the Board is a strategic move that leverages his extensive experience in the healthcare sector and capital markets. Watson’s proven track record in negotiating significant capital transactions and leading successful exits will be invaluable as CEL-SCI navigates the final stages of Multikine’s approval process. The promising results from the Multikine trials, showing a significant survival rate improvement for head and neck cancer patients, highlight the potential impact of this innovative immunotherapy. With the FDA’s approval for a focused Registration Study, CEL-SCI is well-positioned to make significant strides in cancer treatment, addressing a high unmet need in the market.
